Human adenosine A2A receptor : molecular mechanism of ligand binding and activation by Carpenter, Byron & Lebon, Guillaume
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Carpenter, Byron and Lebon, Guillaume. (2017) Human adenosine A2A receptor : molecular 
mechanism of ligand binding and activation. Frontiers in Pharmacology, 8 . 898.  
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/96391                      
       
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 4.0 International 
license (CC BY 4.0) and may be reused according to the conditions of the license.  For more 
details see: http://creativecommons.org/licenses/by/4.0/   
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may be 
cited as it appears here. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
REVIEW
published: 14 December 2017
doi: 10.3389/fphar.2017.00898
Frontiers in Pharmacology | www.frontiersin.org 1 December 2017 | Volume 8 | Article 898
Edited by:
Kenneth A. Jacobson,
National Institutes of Health (NIH),
United States
Reviewed by:
Fei Xu,
ShanghaiTech University, China
Kate White,
University of Southern California,
United States
*Correspondence:
Byron Carpenter
b.carpenter@warwick.ac.uk
Guillaume Lebon
glebon@igf.cnrs.fr
Specialty section:
This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology
Received: 24 October 2017
Accepted: 24 November 2017
Published: 14 December 2017
Citation:
Carpenter B and Lebon G (2017)
Human Adenosine A2A Receptor:
Molecular Mechanism of Ligand
Binding and Activation.
Front. Pharmacol. 8:898.
doi: 10.3389/fphar.2017.00898
Human Adenosine A2A Receptor:
Molecular Mechanism of Ligand
Binding and Activation
Byron Carpenter 1* and Guillaume Lebon 2*
1Warwick Integrative Synthetic Biology Centre, School of Life Sciences, University of Warwick, Coventry, United Kingdom,
2 Institut de Génomique Fonctionnelle, Neuroscience Department, UMR CNRS 5203, INSERM U1191, Université de
Montpellier, Montpellier, France
Adenosine receptors (ARs) comprise the P1 class of purinergic receptors and belong
to the largest family of integral membrane proteins in the human genome, the G
protein-coupled receptors (GPCRs). ARs are classified into four subtypes, A1, A2A,
A2B, and A3, which are all activated by extracellular adenosine, and play central roles
in a broad range of physiological processes, including sleep regulation, angiogenesis
and modulation of the immune system. ARs are potential therapeutic targets in a
variety of pathophysiological conditions, including sleep disorders, cancer, and dementia,
which has made them important targets for structural biology. Over a decade of
research and innovation has culminated with the publication of more than 30 crystal
structures of the human adenosine A2A receptor (A2AR), making it one of the best
structurally characterized GPCRs at the atomic level. In this review we analyze the
structural data reported for A2AR that described for the first time the binding of mode
of antagonists, including newly developed drug candidates, synthetic and endogenous
agonists, sodium ions and an engineered G protein. These structures have revealed the
key conformational changes induced upon agonist and G protein binding that are central
to signal transduction by A2AR, and have highlighted both similarities and differences in
the activation mechanism of this receptor compared to other class A GPCRs. Finally,
comparison of A2AR with the recently solved structures of A1R has provided the first
structural insight into the molecular determinants of ligand binding specificity in different
AR subtypes.
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Key Concepts
1. A2AR crystallization: selection of different conformational states
Structure determination of A2AR required the application of novel protein engineering
techniques to lock the receptor in defined conformational states and facilitate the growth of
crystals that diffract to high resolution.
2. Structural determinants of A2AR ligand binding and selectivity
The atomic resolution structural features of A2AR that dictate which ligands it can bind and
whether the ligands act as agonists, to promote signaling, or antagonists, to block signaling.
3. Ligand-induced activation of A2AR
The molecular changes that are induced in A2AR by agonist binding, which facilitate G protein
coupling and ultimately signal transduction.
4. Structural diversity of the adenosine receptor family
The difference in the primary and ternary structure between the four AR subtypes that is
ultimately responsible for their ligand-binding specificity and pharmacological profiles.
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INTRODUCTION
Purinergic signaling is predominantly mediated by extracellular
purine nucleosides and nucleotides, including adenosine and
adenosine triphosphate (ATP), but also by purine bases such
as caffeine and xanthine. Purinergic receptors are integral
membrane protein that are divided into three classes, P1 (better
known as adenosine receptors), P2Y, and P2X (Burnstock, 2006).
Both P1 and P2Y receptors belong to the G protein-coupled
receptor (GPCR) family, whereas P2X receptors are ATP-gated
ion channels. Adenosine receptors (ARs) are divided into four
subtypes, A1, A2A, A2B, and A3 (Fredholm et al., 2001), which
are broadly expressed in the central nervous system as well as
peripheral tissues of the cardiovascular, respiratory, renal, and
immune systems (Fredholm et al., 2001, 2011). Extracellular
adenosine is the endogenous agonist for all ARs, however
differences in the adenosine binding affinity, tissue distribution,
expression level and G protein coupling preference between the
subtypes gives each a distinct signaling profile (Cieslak et al.,
2008; Fredholm, 2014). A1R and A3R predominantly activate
heterotrimeric G proteins belonging to the Gαi/o family, which
inhibit cAMP production by adenylate cyclase, in contrast A2AR
and A2BR predominantly activate Gαs family members, which
stimulate cAMP production (Jacobson and Gao, 2006). G protein
βγ subunits also contribute to signaling through the mitogen-
activated protein kinase (MAPK) and phospholipase C (PLC)
pathways (Jacobson and Gao, 2006). ARs mediate the general
cytoprotective functions associated with extracellular adenosine,
with some of the key physiological processes regulated by
individual subtypes being: sleep, vasoconstriction and inhibition
of neurotransmitter release by A1R; sleep, angiogenesis, and
immunosuppression by A2AR; vascular integrity and myocardial
preconditioning by A2BR; mast cell regulation and myocardial
preconditioning by A3R (Fredholm et al., 2011).
ARs have been proposed as potential targets in a wide
variety of pathophysiological conditions, including arrhythmia,
ischemia, sleep disorders, pain, dementia, Parkinson’s, renal
failure, asthma, type 2 diabetes, glaucoma, inflammation,
and cancer (Jacobson and Gao, 2006; Cieslak et al., 2008;
Sawynok, 2016). However, one of the challenges of therapeutic
intervention has been targeting individual AR subtypes with
sufficient specificity to limit off-target side effects (Chen et al.,
2013). Medicinal chemistry approaches have been used to
develop an array of compounds that exhibit improved subtype
specificity (Müller and Jacobson, 2011), but very few have been
approved for clinical use, due in part to the persistence of
undesirable side effects (Chen et al., 2013; Glukhova et al., 2017).
Further improvements in subtype specificity, coupled with the
development of allosteric modulators (Gentry et al., 2015) that
bind outside the orthosteric site, and biased ligands (Kenakin
and Christopoulos, 2013) that can target a distinct signaling
pathway associated with an individual AR subtype, may help
to eliminate side effects entirely. Structure-based drug design,
which involves in silico screening of vast compound libraries
against experimentally determined receptor structures, offers
huge potential for the development of a new generation of highly
selective orthosteric, allosteric, and biased ligands, however, the
difficulty of crystallizing GPCRs has, until recently, hindered this
approach (Jazayeri et al., 2015).
Structure determination of GPCRs is notoriously challenging
due to their conformationally dynamic nature and poor
thermostability when extracted from the plasma membrane.
During the past decade crystallization strategies have been
developed that have revolutionized the structural biology of
GPCRs, these include protein engineering approaches, such
as fusion proteins (Cherezov et al., 2007; Chun et al., 2012),
antibodies (Rasmussen et al., 2007, 2011a) and conformational
thermostabilization (Magnani et al., 2008; Serrano-Vega et al.,
2008; Shibata et al., 2009), as well as technical developments, such
as the lipidic cubic phase (LCP) (Landau and Rosenbusch, 1996;
Caffrey, 2015). Human A2AR has been at the forefront of this
revolution and is now one of the best structurally characterized
GPCRs, with more than 30 structures deposited in the protein
data bank (PDB; Table 1). It is the only receptor for which
structures of three distinct activation states have been reported,
namely the inactive conformation bound to an antagonist or
inverse agonist (Jaakola et al., 2008), an intermediate-active
conformation bound to an agonist (Lebon et al., 2011b; Xu et al.,
2011), and the active conformation bound to both an agonist and
engineered G protein (Carpenter et al., 2016). Crystallization of
the other AR subtypes has proved more difficult and it is only
during the past year that structures of A1R have been published
(Cheng et al., 2017; Glukhova et al., 2017). Significantly, these
have provided the first atomic resolution insight in to the
molecular determinants of ligand binding specificity in different
AR subtypes.
In this review we consolidate and analyze all of the structural
information published during the past decade, which provides
a near complete picture of A2AR activation. We compare the
binding mode of antagonists, including the widely consumed
stimulant caffeine (Doré et al., 2011; Cheng et al., 2017), and
agonists, including the endogenous ligand adenosine (Lebon
et al., 2011b). We highlight the agonist-induced conformational
changes that activate A2AR (Lebon et al., 2011b; Xu et al., 2011),
and the cooperative conformational changes induced by G
protein coupling (Carpenter et al., 2016). Finally, we compare
A2AR with the recently solved structures of A1R (Cheng et al.,
2017; Glukhova et al., 2017) and discuss the current evidence for
the molecular basis of ligand binding specificity in different AR
subtypes.
A2AR CRYSTALLIZATION: SELECTION OF
DIFFERENT CONFORMATIONAL STATES
GPCRs are challenging targets for structural studies for three
main reasons. First, flexibility and conformationally dynamics
play a central role in receptor activation by maintaining a
dynamic equilibrium between different conformational states
(Kobilka and Deupi, 2007). Ligand binding is often insufficient
to trap the receptor in a distinct conformation (Manglik
et al., 2015; Ye et al., 2016), which can perturb the growth
of crystals that diffract to high resolution (Cherezov et al.,
2007; Warne et al., 2008; Tate and Schertler, 2009). Second,
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TABLE 1 | Adenosine receptor X-ray crystal structures.
Receptor
subtype
Conformational
state
Ligand class Ligand name Fusion
protein
Thermostabilized Binding
partner
Resolution
(Å)
PDB code References
A1 Inactive Antagonist DU172
a BRIL No None 3.2 5UEN Glukhova et al., 2017
Inactive Antagonist PSB36 BRIL Yes None 3.3 5N2S Cheng et al., 2017
A2A Inactive Inverse agonist ZM241385 T4L No None 2.6 3EML Jaakola et al., 2008
Inactive Inverse agonist ZM241385 None Yes None 3.3 3PWH Doré et al., 2011
Inactive Antagonist XAC None Yes None 3.3 3REY Doré et al., 2011
Inactive Antagonist Caffeine None Yes None 3.6 3RFM Doré et al., 2011
Inactive Inverse agonist ZM241385 BRIL No None 1.8 4EIY Liu et al., 2012
Inactive Antagonist T4Gb None Yes None 3.3 3UZA Congreve et al., 2012
Inactive Antagonist T4Eb None Yes None 3.3 3UZC Congreve et al., 2012
Inactive Inverse agonist ZM241385 None No Fab2823 2.7 3VG9 Hino et al., 2012
Inactive Inverse agonist ZM241385 None No Fab2823 3.1 3VGA Hino et al., 2012
Inactive Inverse agonist ZM241385 BRIL Yes None 1.7 5IU4 Segala et al., 2016
Inactive Antagonist 6DYb BRIL Yes None 1.9 5IU7 Segala et al., 2016
Inactive Antagonist 6DZb BRIL Yes None 2.0 5IU8 Segala et al., 2016
Inactive Antagonist 6DXb BRIL Yes None 2.2 5IUA Segala et al., 2016
Inactive Antagonist 6DVb BRIL Yes None 2.1 5IUB Segala et al., 2016
Inactive Inverse agonist ZM241385 BRIL No None 2.5 5K2A Batyuk et al., 2016
Inactive Inverse agonist ZM241385 BRIL No None 2.5 5K2B Batyuk et al., 2016
Inactive Inverse agonist ZM241385 BRIL No None 1.9 5K2C Batyuk et al., 2016
Inactive Inverse agonist ZM241385 BRIL No None 1.9 5K2D Batyuk et al., 2016
Inactive Inverse agonist ZM241385 BRIL No None 2.8 5JTB Melnikov et al., 2017
Inactive Antagonist 8D1b BRIL No None 3.5 5UIG Sun et al., 2017
Inactive Inverse agonist ZM241385 BRIL No None 3.2 5UVI Martin-Garcia et al., 2017
Inactive Antagonist Caffeine BRIL Yes None 2.1 5MZP Cheng et al., 2017
Inactive Antagonist Theophylline BRIL Yes None 2.0 5MZJ Cheng et al., 2017
Inactive Antagonist PSB36 BRIL Yes None 2.8 5N2R Cheng et al., 2017
Inactive Inverse agonist ZM241385 BRIL Yes None 2.1 5NLX Weinert et al., 2017
Inactive Inverse agonist ZM241385 BRIL Yes None 2.0 5NM2 Weinert et al., 2017
Inactive Inverse agonist ZM241385 BRIL Yes None 1.7 5NM4 Weinert et al., 2017
Intermediate-active Agonist UK-432097 T4L No None 2.7 3QAK Xu et al., 2011
Intermediate-active Agonist Adenosine None Yes None 3.0 2YDO Lebon et al., 2011b
Intermediate-active Agonist NECA None Yes None 2.6 2YDV Lebon et al., 2011b
Intermediate-active Agonist CGS21680 None Yes None 2.6 4UG2 Lebon et al., 2015
Intermediate-active Agonist CGS21680 None Yes None 2.6 4UHR Lebon et al., 2015
Active Agonist NECA None No Mini-Gs 3.4 5G53 Carpenter et al., 2016
aCovalently bound antagonist.
bLigand nomenclature as used in the PDB.
GPCRs are highly unstable upon extraction from the membrane
by detergent solubilization, which makes purification of the
receptors both technically challenging and inefficient (Serrano-
Vega et al., 2008). Third, class A receptors are compact
proteins that typically have onlyminimal hydrophilic surface area
capable of forming crystal contacts. Structure determination of
virtually all GPCRs, including A2AR, has therefore required the
development of novel protein engineering strategies (discussed
below), crystallization techniques, including LCP (Landau and
Rosenbusch, 1996; Xu et al., 2011; Caffrey, 2015), and data
collection methods, including the use of micrometer-sized X-ray
beams (Moukhametzianov et al., 2008) or serial crystallography
(Weinert et al., 2017), in order to obtain well-diffracting crystals
and collect high resolution diffraction data.
The first structure of A2AR was solved bound to the inverse
agonist ZM241385 at 2.6 Å resolution (Jaakola et al., 2008).
This structure was facilitated by a combined approach of using
a high affinity ligand, which locks the receptor in its inactive
state, and by replacing the third intracellular loop (ICL3)
with a T4 lysozyme (T4L) fusion protein (Rosenbaum et al.,
2007), which increases the hydrophilic surface area available
for crystal contact formation (Figure 1A). This fusion protein
strategy was subsequently modified to utilize apocytochrome
b562RIL (BRIL) instead of T4L (Liu et al., 2012), which
resulted in the solution of seven additional structures of A2AR
bound to ZM241385 ranging in resolution from 3.2 to 1.8
Å (Liu et al., 2012; Batyuk et al., 2016; Martin-Garcia et al.,
2017; Melnikov et al., 2017), and one structure bound to the
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FIGURE 1 | Protein engineering strategies used for the selection and crystallization of distinct A2AR conformations. (A) Crystal structure of A2AR (colored green) in the
inactive conformation bound to the inverse agonist ZM241385 (shown as spheres, carbon atoms colored orange) with T4 lysozyme (T4L; colored blue) fused between
the intracellular ends of H5 and H6 (PDB: 3EML) (Jaakola et al., 2008). The T4L fusion protein has also been substituted with apocytochrome b562RIL (BRIL; not
shown) (Liu et al., 2012). (B) Structure of A2AR in the inactive conformation bound to ZM241385 (shown as spheres, carbon atoms colored orange) and an antibody
Fab fragment (colored cyan) that acts as an intracellular inverse agonist (PDB: 3VG9 and 3VGA) (Hino et al., 2012). (C) Crystal structure of thermostabilized
A2AR-GL26 in the intermediate-active conformation bound to the agonist adenosine (shown as spheres, carbon atoms colored magenta), the four thermostabilizing
mutations (L48A2.46, A54L2.52, T65A2.63, and Q89A3.37) are shown as spheres and their carbon atoms colored yellow (PDB: 2YDO) (Lebon et al., 2011b). In the
expanded view the residues with which the thermostabilizing mutations interact (distance < 4 Å) are shown as sticks. Conformational thermostabilization has
facilitated the crystallization of A2AR in both the agonist- and antagonist- bound conformations. (D) Structure of A2AR in the active conformation bound to NECA
(shown as spheres, carbon atoms colored light pink) and an engineered G protein mini-Gs (colored brown; PDB: 5G53) (Carpenter et al., 2016). Figures were
prepared using PyMOL (PyMOLTM Molecular Graphics System, Version 1.8.6.0).
antagonist 8D1 (Sun et al., 2017) (Table 1). Conformational
thermostabilization, which utilizes alanine scanning mutagenesis
to identify point mutations that stabilize the receptor in a
particular conformational state and increase its thermostability in
detergent (Magnani et al., 2008, 2016), was also applied to solve
the structure of A2AR bound to ZM241385 (Doré et al., 2011).
The construct A2AR-StaR2 contained eight thermostabilizing
mutations (A54L2.52, T88A3.36, R107A3.55, K1224.43, L202A5.63,
L235A6.37, V239A6.41, and S277A7.42; superscripts refer to
Ballesteros–Weinstein numbering) (Ballesteros and Weinstein,
1995) that increased the stability of the receptor in the detergent
dodecylmaltoside (DDM) by ∼18◦C. A2AR-StaR2 has since
been crystallized bound to four different antagonists XAC,
caffeine, T4G and T4E (Doré et al., 2011; Congreve et al.,
2012). Conformational thermostabilization has also been used
in combination with a BRIL fusion protein to facilitate the
crystallization of A2AR bound to the antagonists 6DY, 6DZ,
6DX, 6DV, ZM241385, caffeine, theophylline, and PSB36 (Segala
et al., 2016; Cheng et al., 2017). Furthermore, ZM241385-bound
A2AR has been co-crystallized in complex with an antibody Fab
fragment (Fab2823), which acts as an intracellular inverse agonist
locking the receptor in its inactive conformation, and also helps
to increase the hydrophilic protein surface available for crystal
contact formation (Figure 1B) (Hino et al., 2012).
The first agonist bound structure of A2AR was solved in
complex with the synthetic agonist UK-432097, using the
T4L fusion strategy (Xu et al., 2011). This ligand is large,
approximately three times the molecular weight of adenosine,
and imparts a significant increase in thermostability to the
receptor. Crystallization of A2AR bound to smaller less stabilizing
agonists required the application of the conformational
thermostabilization methodology (Figure 1C). In this case the
receptor was thermostabilized in the presence of the agonist
NECA, and four mutations (L48A2.46, A54L2.52, T65A2.63, and
Q89A3.37) were combined in the final construct (A2AR-GL26)
(Lebon et al., 2011a). The stability of A2AR-GL26 was ∼16◦C
higher than the wild type receptor in DDM, which facilitated
structure determination of the receptor in complex with the small
agonists adenosine and NECA (Lebon et al., 2011b), as well as
the larger CGS21680 (Lebon et al., 2015). All four agonist-bound
structures adopted a conformation that was different from the
inactive state, but that did not fully resemble the active state of the
β2 adrenergic receptor (β2AR) in complex with heterotrimeric
Gs (Rasmussen et al., 2011b), this conformation was therefore
defined as the intermediate-active state (Lebon et al., 2011b).
Interestingly, the high affinity agonist UK-432097 was sufficiently
stabilizing to allow the crystallization of non-thermostabilized
A2AR in the intermediate-active state. This is likely due to
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the large size of the ligand, which results in it forming more
extensive molecular contacts with the receptor, in particular
UK-432097 forms four additional direct hydrogen bonds with
A2AR compared to adenosine. In the case of small low affinity
agonists, such as adenosine, conformational thermostabilization
was absolutely necessary to facilitate structured determination.
The agonist-bound A2AR structures exhibited some
characteristics of the active receptor (Lebon et al., 2012), however
stabilizing the fully active conformation requires simultaneous
binding of the agonist and G protein or a functional mimetic
(Rasmussen et al., 2011a,b). Co-crystallization of GPCRs
in complex with heterotrimeric G proteins is the ideal case
for characterizing receptors in their active state, however
this approach is challenging, due in part to the large size
and conformationally dynamic nature of the G protein
(Westfield et al., 2011). The development of nanobodies that
act as surrogates of heterotrimeric G proteins has proved
to be a powerful approach to crystallize receptors in their
active conformation (Steyaert and Kobilka, 2011), however
the disadvantage of this method is that nanobodies do not
recapitulate the native GPCR–G protein interface. Structure
determination of A2AR in its active conformation was achieved
using a recently developed minimal G protein, which is
composed of a single engineered domain from the Gαs subunit
(Figure 1D) (Carpenter and Tate, 2016, 2017b,c). This mini G
protein (mini-Gs) sufficiently stabilized NECA-bound A2AR
in its fully active conformation to facilitate crystallization
and structure determination at 3.4 Å resolution (Carpenter
et al., 2016). This approach has now been applied to most
heterotrimeric G proteins (Nehmé et al., 2017) and should play
an important role solving high-resolution structures of other
GPCRs in their active state (Strege et al., 2017).
STRUCTURAL DETERMINANTS OF A2AR
LIGAND BINDING AND SELECTIVITY
The orthosteric binding site of A2AR can be defined by the
residues involved in binding the endogenous agonist adenosine
and the naturally occurring antagonist caffeine (see Figure 2
for the ligand structures and atom numbering, and Table 2
for A2AR-ligand contacts). Adenosine and caffeine share a
common xanthine moiety that in both cases establishes van
der Waals interactions with M1775.38, M2707.35 and I2747.39,
and a pi-stacking interaction with the aromatic ring of F168,
which is part of the helical portion of extracellular loop 2
(ECL2; Figures 3, 4) (Doré et al., 2011; Lebon et al., 2011b;
Cheng et al., 2017). N2536.55 forms hydrogen bonds with either
the amine groups at positions C6 and N7 of the adenine
moiety of adenosine (Lebon et al., 2011b) or O11/O13 from
the xanthine heterocycle of caffeine, for which two distinct
binding orientations have been observed (Cheng et al., 2017).
The ribose moiety of adenosine forms van derWaals interactions
with V843.32, L853.33, T883.36, W2466.48, and L2496.51; these
residues form similar contacts with many antagonist. The main
difference between the adenosine- and caffeine-binding modes
is the formation of hydrogen bonds from the hydroxyl groups
FIGURE 2 | Two dimensional structures of the endogenous A2AR agonist
adenosine and the naturally occurring antagonist caffeine. The atom
numbering indicated is used in the text to describe the binding of these ligands
and their derivatives to A2AR.
at positions C2 and C3 of the ribose moiety of adenosine to
S2777.42 and H2787.43. The recent high-resolution structure of
A2AR bound to caffeine (2.10 Å) did reveal a water-mediated
contact between H2787.43 and O11 of caffeine (Cheng et al.,
2017). However, the presence of this water molecule highlights
the difference in the distance between these atoms compared to
the adenosine-bound state, where a direct interaction is observed.
This distance is reduced concomitantly with the conformational
changes in H3 and H7 associated with agonist binding to the
receptor (Figure 5) (Lebon et al., 2012). All agonists that have
been co-crystallized with A2AR engage H3 through T883.36 and
H7 through S2777.42/H2787.43 (Table 2). Some antagonists do
interact with either T883.36 or S2777.42/H2787.43, but never at the
same time, which suggests that the simultaneous engagement of
these residues in H3 and H7 may be a key determinant of agonist
activity.
Structures of A2AR have been solved in complex with three
high-affinity synthetic agonists NECA, CGS21680 and UK-
432097 (Lebon et al., 2011b, 2015; Xu et al., 2011). These
agonists share a core adenosine moiety, the binding mode of
which is very similar to adenosine itself, with the ribose group
establishing hydrogen bonds with S2777.42 and H2787.43. For
all three ligands the N-ethylcarboxyamido tail at position C5′
of the ribose ring extends deep into the binding pocket. The
nitrogen and oxygen atoms form polar contacts with T883.36 and
H2506.52, respectively, and the substituent is further stabilized
by van der Waals interactions with N1815.42, W2466.48 and to a
lesser extent Q/A3.37. In contrast, the OH group at this position
of adenosine interacts with N1815.42 andH2506.52 through water-
mediated interactions and M1775.38 through a van der Waals
interaction. The major difference between the binding mode
of these agonists can be seen in the extracellular loops of the
receptor. NECA and adenosine are both stabilized by a hydrogen
bond with E169ECL2 (Lebon et al., 2011b); this residue also forms
a salt bridge with H264ECL3, which closes the top of the binding
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TABLE 2 | A2AR-ligand interactions.
Secondary
structure
element
A2AR
residue
Ligand (agonist/antagonist)
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A2AR residues that directly interact with each ligand (distances < 4 Å) are indicated by filled cells and colored according to the ligand type with which they interact (agonists only,
red; antagonists only, blue; both agonists and antagonists, gray). Residues F168ECL2, M1775.38, L2496.51, N2536.55 and I2747.39 interact with all agonists and antagonists for which
structures have been solved and are indicated by filled cells colored green. T883.36 interacts with all agonists for which structures have been solved and is a key residue in agonist-
induced receptor activation, however since it also interacts with the antagonist 8D1 (discussed in the text) it is indicated by hatched cells colored red. The secondary structure element
in which each residue is located is shown in the left hand column (H, transmembrane helix; ECL, extracellular loop). The PDB codes of the A2AR structures used for analysis are shown
in parentheses next to each ligand. Note that several of the A2AR structures contain thermostabilizing mutations, including T88A/S277A (caffeine, theophylline, T4G, T4E, XAC, 6DX,
6DZ, 6DY, 6DV, PSB36) and Q89A (adenosine, NECA and CGS21680).
pocket and is known to affect ligand binding kinetics (Guo et al.,
2016; Segala et al., 2016). CGS21680 takes advantage of similar
hydrogen bond between the amine group at position C6 of
adenine moiety and E169ECL2 (Lebon et al., 2015). The larger
(2-carboxyethyl)phenylethylamino substituent at the C2 position
protrudes outside the binding pocket and is stabilized by van
der Waals interactions with E169ECL2, H264ECL3, and L2677.32
as well as a hydrogen bond with S672.65. As a consequence, the
extracellular end of H2 is displaced inward compared to other
agonist-bound structures, reducing the volume of the binding
pocket. UK-432097 has two substituents on the adenine moiety,
that make it an even larger molecule than CGS21680. The
consequence is that the bulky 2-(3-[1-(pyridine-2-yl)piperidin-4-
yl]ureido)ethylcarboxamido substitution at position C2 displaces
ECL3 away from the binding pocket, which induces rotamer
changes in E169ECL2 and H264ECL3 and breaks the salt
bridge between these side chains (Xu et al., 2011). The
urea group forms two hydrogen bonds with E169ECL2 as
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FIGURE 3 | High-resolution view of the agonist-binding site of human A2AR. Four different agonists have been co-crystallized with A2AR in the intermediate-active
conformation. The receptor is shown as cartoons and colored gray, residues and side chains that interact with the ligand are shown as sticks and colored by element
(carbon, gray; nitrogen, blue; oxygen, red; sulfur, yellow). The ligands are shown as sticks and their carbon atoms are colored to match their labels, PDB codes are
shown in the figure. Polar contacts are represented as dashed lines and water molecules are shown as red spheres.
well as a hydrogen bond and van der Waals interactions
with Y2717.36 on its opposite side. The pyridinyl-piperidine
group, which extends furthest from the binding pocket, is
stabilized by van der Waals interactions with L2677.32 and
H264ECL3.
Like agonists, antagonists can exploit subsidiary binding
sites by expanding their contact surface outside the orthosteric
binding pocket. Starting with ZM241385, the trizolotriazine ring
occupies the orthosteric binding site, and is surrounded by
F168ECL2, L2496.51, M2707.35, I2747.39. Two residues, E169ECL2
and N2536.55, form hydrogen bonds with the amine group of
the ZM241385 heterocycle and an additional hydrogen bond is
established between N2536.55 and the oxygen of the furan ring.
The formation of van der Waals interactions with M1775.38,
W2466.48, L2496.51, and H2506.52 stabilize H5 and H6 against
the furan ring. ZM241385 explores the chemical space outside
the orthosteric site by taking advantage of the cavity on the
extracellular surface of the receptor. Two distinct orientations
have been observed for the phenol ring of ZM241385, in the first
conformation the salt bridge between E169ECL2 and H264ECL3
is intact and the phenol ring forms van der Waals interactions
with H264ECL3, L2677.32 and M2707.35 (Jaakola et al., 2008).
Interestingly, the phenylethylamine group of ZM241385 adopts
a binding mode similar to the (2-carboxyethyl)phenylethylamino
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FIGURE 4 | High-resolution view of the antagonist- or inverse agonist- binding site of human A2AR. Twelve different antagonists or inverse agonists have been
co-crystallized with A2AR, in the inactive conformation. The receptor is shown as cartoons and colored gray, residues and side chains that interact with the ligand are
shown as sticks and colored by element (carbon, gray; nitrogen, blue; oxygen, red; sulfur, yellow). The ligands are shown as sticks and their carbon atoms are colored
to match their labels, PDB codes are shown in the figure. Polar contacts are represented as dashed lines and water molecules are shown as red spheres. Note that
for caffeine the two distinct binding orientations that were observed in the structure are overlaid.
substituent of CGS21680 (Lebon et al., 2015). The second
conformation was observed in a thermostabilized receptor
structure where the salt bridge between E169ECL2 and H264ECL3
is broken (Doré et al., 2011). In this case the phenol moiety
is pointing toward H1 and H2 engaging S672.65, Y2717.36,
and I2747.39 through van der Waals interactions and A632.61
through a hydrogen bond. Both Y91.35 and Y2717.36 sidechains
adopt different rotamers in order to accommodate the phenol
substituent in this pose, demonstrating that this subsidiary
pocket is conformationally malleable. The xanthine derivative
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XAC occupies the orthosteric pocket with the xanthine ring
adopting a similar position to caffeine and the trizolotriazine
heterocycle of ZM241385 (Doré et al., 2011). However, the
xanthine core is branched at position N1 and N3; the N3 propyl
substituent forms van der Waals interactions with I662.64 and
A813.29 that are not observed for ZM241385. On the extracellular
surface of the receptor the phenoxy-acetamide tail of XAC adopts
a pose that is similar to the phenol group of ZM241385 in the
thermostabilized receptor structure and is engaged by S672.65,
L2677.32, M2707.35, Y2717.36, and I2747.39. However, none of
these interactions are unique to XAC since they are all observed
for ZM241385 in either of its two poses. The recent structure
of 8D1 (also known as compound-1) bound to A2AR provides
another example of a ligand that exploits this subsidiary binding
site (Sun et al., 2017). The methoxy phenyl substituent of 8D1
occupies the extracellular pocket formed by Y91.35, A632.61,
I662.64, S672.65, L2677.32, M2707.35, Y2717.36, and I2747.39 in
a similar way to XAC and ZM241385. In this case a unique
interaction is observed between 8D1 and Y91.35 that is not
observed for any other ligand (Table 2). Thus, several different
ligands and chemical substituents have been shown to take
advantage of the subsidiary binding pocket located between H1,
H2, and H7 on the extracellular surface of the receptor.
Cavities identified from high-resolution crystal structures
provide valuable information for structure-based drug discovery.
This can be best illustrated by the study of Congreve et al. who
have reported the discovery of 1,2,4-triazine derivatives as A2AR
antagonists by exploiting structural data (Congreve et al., 2012).
The authors optimized a series of compounds and hypothesized
that 1,2,4-triazine derivatives may occupy the same area of the
binding pocket as the ribose moiety of agonists. Solution of
the corresponding ligand–receptor structures showed that the
triazine ring of T4E or T4G sits in a pocket similar to other
ligands, and forms van der Waals interactions with F168ECL2 and
two hydrogen bonds withN2536.55. The phenol substituent forms
van der Waals interactions with L853.33, M1775.38, W2466.48
L2496.51, and H2506.52. As predicted the dimethyl-pyridine
group of T4G occupies the ribose pocket and the phenolic
hydroxyl group of T4E establishes a hydrogen bond with
H2787.43, but importantly the ligands retain their antagonistic
properties.
Crystallographic studies have also highlighted the role that
ECL2 and ECL3 play in ligand binding, specifically the effect
of the salt bridge between E169ECL2 and H264ECL3 (Lebon
et al., 2015; Guo et al., 2016; Segala et al., 2016). These two
residue as well as the salt bridge that they form, stabilize
several ligands in the binding pocket, as described above for
ZM241385. The phenol ring of the ZM241385 has recently been
replaced by a set of larger substitutions and their structures
have been solved in complex with A2AR at high resolution
(Segala et al., 2016). The substitutions were reported to affect
the residence time of the ligands, with the ligand 6DV (also
known as 12x) displaying the slowest off-rate. This observation
is also in agreement with the agonist-bound structures where
the salt bridge closes the binding site for adenosine, NECA
and CGS21680 (Lebon et al., 2011b, 2015). Mutation of either
E169ECL2 or H264ECL3 has been shown to impair the potency of
NECA whereas only mutation of H264ECL3 affected CGS21680
(Lebon et al., 2015). The lower potency of agonists on these
mutant receptors might be a consequence of a faster off-rate
in absence of the salt bridge, however it appears that the
stabilizing effect of the salt bridge can be compensated for by
extended molecular contact formed by large molecules, such as
CGS21680.
LIGAND-INDUCED ACTIVATION OF A2AR
GPCRs exist in dynamic equilibrium between several discrete
conformational states that are separated by energy barriers
(Manglik et al., 2015; Ye et al., 2016). The inactive and
active states are well-conserved between GPCRs (Rosenbaum
et al., 2009; Carpenter and Tate, 2017a), however a number
of intermediate conformations have been identified that appear
to be more divergent (Lebon et al., 2011b; Xu et al., 2011;
White et al., 2012; Manglik et al., 2015; Ye et al., 2016). Agonist
binding to the receptor is one of the key events required
to overcome the energy barrier of activation and increase
occupancy of the conformational state(s) that are capable of
binding heterotrimeric G proteins (Manglik et al., 2015; Ye et al.,
2016; Prosser et al., 2017). A2AR is one of the only receptors
for which an intermediate-active agonist-bound state has been
crystallized (Lebon et al., 2011b; Xu et al., 2011). This structure
has provided unique insight into the molecular changes that
occur during two key activation events, namely agonist-induced
transition from the inactive to intermediate-active state and G
protein-induced transition from the intermediate-active to active
state. The structures used for comparison are the inactive state
bound to the inverse agonist ZM241385 (Doré et al., 2011;
Liu et al., 2012), the intermediate-active state bound to the
agonist NECA (Lebon et al., 2011b) and the active state bound
to NECA and mini-Gs (Carpenter et al., 2016), see Figure 5.
Agonist binding to A2AR triggers a series of conformational
changes, most notably within the ligand-binding pocket and
on the intracellular side of the receptor (Figure 5A). In the
ligand binding pocket the most significant changes are a 2 Å
translocation of H3 along its axis that is necessary to prevent
steric clashes of V843.32 and L853.33 with NECA, the formation
of contacts between the ribose moiety of the agonist and residues
S2777.42 and H2787.43 in H7 that are completely absent in the
inverse agonist-bound state, and an inward bulge in H5 that
disrupts the local helix geometry and shifts C1855.46 toward
the core of the receptor by 4 Å (Lebon et al., 2011b). Notably,
the bulge in H5 has a knock-on effect on the position of
H2506.52, which is shifted toward the ligand by 2 Å, a movement
that would be sterically forbidden if the inverse agonist were
bound (Lebon et al., 2011b, 2012; Xu et al., 2011). This bulge
is also observed in other GPCR structures suggesting it is one
of the key event in activation (Venkatakrishnan et al., 2013).
Agonist binding causes only subtle conformational changes on
the extracellular side of the receptor, including 1-2 Å inward
shifts in the ends of H1, H2, and H3. More significant changes
are observed on the intracellular side, which are thought to prime
the receptor for G protein coupling (Venkatakrishnan et al.,
2016), specifically combined rotations and lateral movements in
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FIGURE 5 | Ligand-induced activation of A2AR. (A) Conformational changes associated with agonist-induced transition from the inactive state (colored cyan) to the
intermediate-active state (colored yellow; PDB: 2YDV) (Lebon et al., 2011b). Two different inactive state structures were used for the alignments, the extracellular view
uses 4EIY (Liu et al., 2012) because it is the highest resolution non-thermostabilized structure available, the intracellular view uses 3PWH (Doré et al., 2011) because it
was crystallized without a fusion protein in ICL3. The extracellular view shows the 1–2 Å inward shifts in the ends of H1, H2, and H3 (indicated by a red arrows), the 2
Å translocation of H3 along its axis (indicated by a dashed red arrow), and the inward bulge in H5 (indicated by a red asterisk). The inverse agonist ZM241385 (colored
cyan) and agonist NECA (colored yellow) are shown as sticks. The intracellular view shows the combined rotational and lateral movements in H5, H6, and H7
(indicated by curved red arrows). H5 and H6 are displaced outwards by 7 and 5 Å, respectively, while H7 moves inwards in by 4 Å. (B) Conformational changes
associated with G protein-induced transition from the intermediate-active state (colored yellow; PDB: 2YDV) (Lebon et al., 2011b) to the active state (colored green;
PDB: 5G53) (Carpenter et al., 2016). No significant changes are observed on the extracellular side of the receptor, and the position of NECA (shown as sticks) is
essentially identical in both states (Carpenter et al., 2016). On the intracellular side of the receptor an outward movement of H6 by 14 Å (indicated by a red arrow) is
required to accommodate binding of mini-Gs (colored magenta). H5 moves inwards by 5 Å (indicated by a red arrow) and forms direct contacts the α5 helix of
mini-Gs. H7 undergoes a rotation, without significant lateral movement (indicated by a curved and dashed red arrow), which reorients the H7-H8 boundary to interact
with the C-terminus of mini-Gs (Carpenter et al., 2016). Note that for clarity, ECL2 has been omitted from the extracellular view of all alignments.
the cytoplasmic ends of H5, H6, and H7, outwards by 7 and
5 Å for H5 and H6, respectively, and inwards by 4 Å for H7
(Figure 5A) (Lebon et al., 2011b; Xu et al., 2011). The ionic
lock between R1023.50 and E2286.30, which is often engaged
in inactive GPCR structures, is broken by the reorientation of
H6.
Sodium ions (Na+) act as negative allosteric modulators
of many class A GPCRs, typically stabilizing the ligand-
free and antagonist-bound states, thereby imposing an energy
barrier on receptor activation (Katritch et al., 2014). The high-
resolution model of A2AR in its inactive state was the first
GPCR structure to reveal the mode of Na+ binding (Liu
et al., 2012). In A2AR the Na+-binding pocket is composed
of residues D522.50, S913.39, T883.36, W2466.48, N2807.45, and
S2817.46; both D522.50 and S913.39 form direct polar interactions
with Na+, whereas interactions with the other residues are
mediated through a network of ordered water molecules (Liu
et al., 2012; Gutiérrez-de-Terán et al., 2013). The conformational
Frontiers in Pharmacology | www.frontiersin.org 10 December 2017 | Volume 8 | Article 898
Carpenter and Lebon Human Adenosine A2A Receptor
changes induced by agonist binding, particularly the rotation
and inward shift of H7 and the outward shift of H6, cause the
Na+-binding pocket to collapse, potentiating the displacement
of Na+, thereby allowing the agonist to overcome the negative
allosteric effect of Na+ and activate the receptor (Gutiérrez-
de-Terán et al., 2013). Interestingly, the intermediate-active
conformation is not observed in crystal structures of agonist-
bound β1AR (Warne et al., 2011) or β2AR (Rosenbaum et al.,
2011). Recent 19F nuclear magnetic resonance (19F NMR) studies
have confirmed the existence of an additional active-like state in
A2AR compared to β2AR (Manglik et al., 2015; Ye et al., 2016;
Prosser et al., 2017), which may correlate with the intermediate-
active conformation observed in the crystal structures, thus
highlighting differences in the energy landscape of activation
between these receptors.
In contrast to the widely distributed effects of agonist binding,
G protein-induced conformational changes are confined to the
intracellular side of the receptor (Figure 5B). G protein coupling
has been reported to increase the agonist-binding affinity of A2AR
between 10- and 40-fold (Murphree et al., 2002; Carpenter et al.,
2016), yet it is striking that the conformation of the residues in
the ligand-binding pocket and the position of the agonist are
essentially identical in both the intermediate-active and active
states (Carpenter et al., 2016). The most likely explanation is that
in the intermediate-active structure the ligand-binding pocket
has already adopted the high-affinity conformation (Carpenter
et al., 2016). However, it cannot be discounted that the relatively
small increase in the agonist-binding affinity of A2AR does
not result from direct changes to the ligand-binding pocket,
for example, a reduction in the conformational dynamics of
the receptor caused by G protein binding could decrease the
off-rate of the agonist, thus increasing its affinity (Carpenter
and Tate, 2017a). On the intracellular side of the receptor the
pivotal event is a 14 Å outward movement of the cytoplasmic
end of H6 to accommodate binding of the α5 helix from
mini-Gs. The outward movement of H6 triggers both a 5 Å
inward movement of H5, positioning it to interact with the
α5 helix of the G protein, and a rotation within H7 that
reorients the H7-H8 boundary to form extensive contacts with
the C-terminus of mini-Gs (Carpenter et al., 2016). These helix
movements also result in reorientation of R1023.50, Y1975.58,
and Y2887.53 side chains within the core of the receptor,
which likely stabilizes the active state, and which is one of the
signatures of a GPCR in its active conformation (Carpenter
and Tate, 2017a). It is clear that the intermediate-active state
of A2AR is incompatible with G protein binding in its final
orientation, i.e., that observed in the A2AR–mini-Gs structure
(Carpenter et al., 2016), due to a large sterically forbidden
clash between the α5 helix of mini-Gs and H6 of the receptor
(Figure 5B). However, it is possible that the intermediate-active
state of A2AR may be responsible for recognition of the G
protein through an initial docking interaction, before cooperative
conformational changes trigger nucleotide dissociation from the
G protein and drive the receptor into its active conformation
(Rasmussen et al., 2011b; Flock et al., 2015; Carpenter et al.,
2016).
STRUCTURAL DIVERSITY OF THE
ADENOSINE RECEPTOR FAMILY
The amino acid sequence of the four AR subtypes is relatively
poorly conserved, A2AR shares only 49, 56, and 39% identity
with A1R, A2BR, and A3R, respectively (aligned over residues
1-312 of A2AR). This means that, despite there being a wealth
of structural data available for A2AR, it has proved challenging
to homology model other AR subtypes with sufficient accuracy
for structure-based drug design applications (Glukhova et al.,
2017). It is only during the past year that structures of an AR
other than A2AR have been published, namely two structures of
A1R bound to the xanthine antagonists DU172 (Glukhova et al.,
2017) and PSB36 (Cheng et al., 2017). The two A1R structures
are closely related and align with an RMSD of 0.6 Å (over
235 Cα atoms), they also align well with the ZM241385-bound
structure of A2AR (Liu et al., 2012), with RMSDs of 0.8 Å (over
238 Cα atoms) and 1.0 Å (over 234 Cα atoms) for the DU172-
and PSB36- bound structures, respectively. The intracellular
side of both A1R structures strongly resemble the ZM241385-
bound A2AR structure (3PWH), which was crystallized without
a fusion protein in ICL3 (Doré et al., 2011), and the ionic lock
between residues R1053.50 and E2296.30 is engaged in both cases
(Cheng et al., 2017; Glukhova et al., 2017). The organization
of the sodium-binding site is also well-conserved between A1R
and A2AR, which supports mutagenesis data that indicated the
negative allosteric effect of sodium on A1Rwasmediated through
this site (Barbhaiya et al., 1996), although neither A1R structure
was of sufficient resolution to conclusively model the sodium ion.
The most striking differences between A1R and A2AR are
the conformational variations in extracellular ends of H1, H2,
H3, and H7 and the orientation of ECL2. In the DU172-bound
structure H3 is displaced inwards by 4 Å, and H1, H2, and H7
are displaced outwards by 5, 4, and 4 Å, respectively (Figure 6A).
The outward movements in H1, H2, and H7 are required to
accommodate the benzene sulfonate group of DU172, which is
covalently linked to Y2717.36, and result in both the expansion
of the orthosteric site and the formation of a secondary allosteric
pocket (Glukhova et al., 2017). Direct comparison of A1R and
A2AR bound to PSB36, which does not contain the benzene
sulfonate substituent, also reveals a partial expansion of the
orthosteric pocket (Cheng et al., 2017), indicating that this region
of A1R is indeed more conformationally malleable than that of
A2AR. Intriguingly, it has been suggested that the conformational
rearrangements in H1, H2, and H3 in A1R may be a direct result
of the different disulphide bond structure of ECL2 (Glukhova
et al., 2017). In both A1R structures ECL2 adopts a similar
conformation, which is different from that observed in any of
the published A2AR structures (Figure 6B). The helical segment
in ECL2 of A1R is extended by five residues and is positioned
almost perpendicular to the transmembrane helices, compared
to the near parallel arrangement in A2AR (Cheng et al., 2017;
Glukhova et al., 2017). There is only a single disulphide bond
in ECL2 of A1R compared to three within the same region of
A2AR, which results in it adopting an extended conformation
(Figure 6B). This appears to reduce conformational constraints
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on the extracellular ends of H2 and H3 allowing them to be
displaced outwards, which in turn influences the positioning of
H1. The displacement of H7 may also be linked to structural
divergence in the extracellular loops, in this case a single amino
acid truncation in ECL3 of A1R has been proposed to induce
the outward tilt observed in the structures (Cheng et al., 2017;
Glukhova et al., 2017).
What do these structures tell us about the molecular
determinants of ligand-binding specificity in different AR
subtypes? First, sequence differences in the binding pocket
do not appear to be the main determinant of ligand-binding
specificity in ARs. The orthosteric binding pocket of A1R
and A2AR in the PSB36-bound structures differ by only four
residues V622.57, N702.65, E170ECL2, and T2707.35 (corresponding
to A592.57, S672.65, L170ECL2, and M2707.35 in A2AR), and of
these, only T/M2707.35 form direct contacts with the ligand
(Cheng et al., 2017). Mutagenesis studies have shown that residue
2707.35 is important in ligand-binding specificity, introducing
the T270M mutation into A1R resulted in decreased binding
affinity of A1R-specific ligands and increased binding affinity of
A2AR-specific ligands, the reverse effect was observed when the
M270T mutation was introduced into A2AR (Cheng et al., 2017;
Glukhova et al., 2017). However, the positioning of this residue
on the extracellular end of H7, at the perimeter of the binding
pocket, suggests its main role is to act as a “gatekeeper” that
regulates ligand access to the orthosteric site (Glukhova et al.,
2017). Second, the topology of the binding pocket appears to
play a central role in ligand-binding specificity. As described
above the disulphide bond structure of ECL1 and ECL2 in
A1R increases mobility in H1, H2 and H3, which causes an
expansion of the binding pocket that is required to accommodate
the benzene sulfonate group of the A1R-selective ligand DU172
(Figure 6A) (Glukhova et al., 2017). Binding pocket topology is
also the predominant factor in the differential binding modes of
PSB36 between A1R and A2AR (Figure 6C). PSB36 binds 2 Å
deeper in the orthosteric pocket of A1R due to the presence of
a channel between H3, H5 and H6 that can accommodate the
butyl substituent at position N1 of the xanthine core (Figure 6C)
(Cheng et al., 2017). This channel is created by a 2 Å displacement
of L883.34 in A1R that appears to be the result of an upstream
proline residue (P863.31), which is located outside the binding
pocket, distorting the helix geometry in this region of H3. A
proline at this position is unique to A1R and helps to explain
why substitutions at position N1 of the xanthine core contribute
to A1R selectivity (Cheng et al., 2017). Thus, the amino acid
sequence both inside and outside the ligand-binding site, the
extracellular loop structure and the topology of the binding
pocket play interconnected roles in governing the ligand binding
affinity and kinetics that are ultimately responsible for the
functional selectivity of AR subtypes.
CONCLUSION
A decade of research and innovation has culminated in the
crystallization of more than 30 structures of human A2AR
in complex with one inverse agonist, 11 antagonists and
four agonists, as well as an engineered G protein. These
FIGURE 6 | Structural diversity of the adenosine receptor family. (A)
Extracellular view of the conformational differences between DU172-bound
A1R (colored magenta; PDB: 5UEN) (Glukhova et al., 2017) and
ZM241385-bound A2AR (colored cyan; PDB: 4EIY) (Liu et al., 2012). The
extracellular ends of H1, H2 and H7 are displaced outwards by 5, 4, and 4 Å,
respectively and H3 is displaced inwards by 4 Å (indicated by red arrows). The
antagonist DU172 (shown as spheres) is covalently attached to Y2717.36
(shown as sticks) through a benzene sulfonate linkage. Note that for clarity,
ECL2 has been omitted from the alignment. (B) Differential conformations of
ECL1 (colored green) and ECL2 (colored blue) in A1R (colored magenta; PDB:
5UEN) (Glukhova et al., 2017) and A2AR (colored cyan; PDB: 4EIY) (Liu et al.,
2012), disulphide bonds are shown as sticks. In A1R ECL2 adopts an
extended conformation that is stabilized by a single disulphide bond
(C803.25-C169ECL2). In contrast, ECL2 from A2AR adopts a compact
conformation that is stabilized by three disulphide bond, one of which
(C773.25-C166ECL2) is conserved in A1R. (C) Surface representation of the
ligand-binding pocket (rendered as semi-transparent mesh) in A1R (colored
blue; PDB: 5N2R) (Cheng et al., 2017) and A2AR (colored green; PDB: 5N2S)
(Cheng et al., 2017), which highlights differences in both the topology of the
orthosteric site and the binding orientation of PSB36 (shown as sticks). The
butyl substituent at position N1 of the xanthine core of PSB36 fits into a
channel between H3, H5, and H6 in A1R, this channel is constricted in A2AR
due to the different orientation of L853.34 (shown as sticks), which results in
the ligand binding in a different orientation.
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structures represent the inactive, intermediate-active and active
conformational states, and A2AR remains the only receptor for
which this complete series of structures has been reported.
Most of the structure were obtained using high affinity ligands,
such as ZM241385, XAC, NECA, UK-432097, CGS21680.
However, the application of conformational thermostabilization
has also facilitated structure determination of the receptor in
complex with lower affinity ligands, including the endogenous
agonist adenosine and the natural plant-derived antagonists
caffeine and theophylline. Structural characterization of the
ligand-binding pocket of A2AR has provide novel insight into
the binding modes of different classes of ligands; the ribose
moiety has been identified as a key component of agonists
that helps to stabilize the intermediate-active state before the
receptor can adopt the fully active conformation upon G
protein coupling. The chemical diversity of compounds co-
crystallized with A2AR has also revealed how some ligands
can exploit subsidiary binding sites on the extracellular surface
of the receptor, as exemplified by the antagonists XAC,
ZM241385, 8D1, T4G, and T4E and agonists CGS21680 and
UK-432097.
High-resolution structures have not only provided a clear
picture of the ligand-binding pocket, but have also highlighted
the impact of receptor flexibility, notably in ECL2 and ECL3,
on the mode and kinetics of ligand binding. Furthermore,
the recently solved structures of A1R revealed that binding
pocket topology and extracellular loop structure are two of the
most important factors affecting the ligand binding specificity
of different AR subtypes. These observations highlight the
challenges of homology modeling GPCRs, since differential
extracellular loop structures, global helix movements and
changes in binding pocket topology are more difficult to model
than amino acid substitutions within the orthosteric site. Thus,
continued efforts to experimentally determine structures of all
four AR subtypes in the three distinct activation states are
essential to maximize the potential of structure based drug design
for this family of receptors. Interestingly, despite the fact that
all ARs are known to signal through G protein-independent
pathways, no biased ligands have thus far been reported for A2AR
(Verzijl and Ijzerman, 2011). Functional selectivity has now
been observed in A1R, A2BR, and A3R (Gao et al., 2014; Baltos
et al., 2016a,b), which suggests that biased ligands could also
be developed for A2AR. However, it is also possible that subtle
differences in the energy landscape and mechanism of A2AR
activation may mean that biased signaling is less pronounced for
this receptor. Therefore, at present A2AR is not an ideal model for
studying functional selectivity, however structural insight from
other GPCRs that have been co-crystallized with biased agonists,
such as β1AR (Warne et al., 2012), may yet help to facilitate the
design biased ligands for A2AR.
Finally, how will the wealth of high-quality structural data
reported for A2AR shape the future of drug development for
this receptor? Structural based design has already been used
to develop novel A2AR antagonists, including a 1,2,4-triazine
derivative that is a preclinical candidate for the treatment of
Parkinson’s disease (Congreve et al., 2012). Further application of
this approach will likely result in the identification of additional
novel compounds, both agonists and antagonists, and will also
facilitate the derivatization and optimization of existing ligands.
The identification of the subsidiary binding pocket on the
extracellular surface of A2AR is an important step toward the
design of allosteric modulators. Exploitation of this pocket has
thus far been achieved using orthosteric ligands with large
substituents that extend outside the orthosteric site, however in
the future it may also be possible to target this region using
purely allosteric ligands. Such compounds have the potential to
modulate the properties of orthosteric ligands, and could thus
be used to fine tune adenosine signaling through individual AR
subtypes.
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